Cargando…
Prognostic significance of angiogenesis in human pancreatic cancer
To evaluate whether angiogenic factors are of clinical relevance to actual human pancreatic cancers, we studied the intratumoral microvessel density (IMD), and PD-ECGF, VEGF protein expression in 40 pancreatic cancers using immunohistochemistry. We also investigated PD-ECGF and VEGF gene expression...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362700/ https://www.ncbi.nlm.nih.gov/pubmed/10188906 http://dx.doi.org/10.1038/sj.bjc.6690248 |
_version_ | 1782153519148564480 |
---|---|
author | Ikeda, N Adachi, M Taki, T Huang, C Hashida, H Takabayashi, A Sho, M Nakajima, Y Kanehiro, H Hisanaga, M Nakano, H Miyake, M |
author_facet | Ikeda, N Adachi, M Taki, T Huang, C Hashida, H Takabayashi, A Sho, M Nakajima, Y Kanehiro, H Hisanaga, M Nakano, H Miyake, M |
author_sort | Ikeda, N |
collection | PubMed |
description | To evaluate whether angiogenic factors are of clinical relevance to actual human pancreatic cancers, we studied the intratumoral microvessel density (IMD), and PD-ECGF, VEGF protein expression in 40 pancreatic cancers using immunohistochemistry. We also investigated PD-ECGF and VEGF gene expression using reverse transcriptase-PCR (RT-PCR). Of the 40 pancreatic cancers studied, 30 carcinomas (75.0%) were evaluated to be PD-ECGF-positive and 10 carcinomas (25.0%) were determined to be PD-ECGF-negative. In contrast, 27 carcinomas (67.5%) were evaluated to be VEGF-positive, whereas 13 carcinomas (32.5%) were VEGF-negative. VEGF gene expression was moderately associated with an increase in the IMD (r(2) = 0.181, P = 0.006), but no significant relationship was found between PD-ECGF gene expression and the IMD (r(2) = 0.093, P = 0.059). However, tumours with positive expression for both PD-ECGF and VEGF had a higher IMD (P = 0.027). The results of the immunohistochemistry agreed well with the results of the quantitative RT-PCR. The median survival time of the hypervascular group was significantly shorter than that of the hypovascular group (P < 0.0001). In comparing the survival according to PD-ECGF and VEGF gene expression, the median survival time of the patients with positive PD-ECGF expression was significantly shorter than those with negative PD-ECGF expression (P = 0.040). Furthermore, the median survival time of the patients with positive VEGF expression was significantly shorter than those with negative VEGF expression (P = 0.048). However, the Cox multivariate analysis indicated that the IMD and VEGF expression were independent prognostic factors of the various clinicopathologic variables in pancreatic cancer patients (P = 0.0021 and P = 0.0443, respectively). © 1999 Cancer Research Campaign |
format | Text |
id | pubmed-2362700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1999 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23627002009-09-10 Prognostic significance of angiogenesis in human pancreatic cancer Ikeda, N Adachi, M Taki, T Huang, C Hashida, H Takabayashi, A Sho, M Nakajima, Y Kanehiro, H Hisanaga, M Nakano, H Miyake, M Br J Cancer Regular Article To evaluate whether angiogenic factors are of clinical relevance to actual human pancreatic cancers, we studied the intratumoral microvessel density (IMD), and PD-ECGF, VEGF protein expression in 40 pancreatic cancers using immunohistochemistry. We also investigated PD-ECGF and VEGF gene expression using reverse transcriptase-PCR (RT-PCR). Of the 40 pancreatic cancers studied, 30 carcinomas (75.0%) were evaluated to be PD-ECGF-positive and 10 carcinomas (25.0%) were determined to be PD-ECGF-negative. In contrast, 27 carcinomas (67.5%) were evaluated to be VEGF-positive, whereas 13 carcinomas (32.5%) were VEGF-negative. VEGF gene expression was moderately associated with an increase in the IMD (r(2) = 0.181, P = 0.006), but no significant relationship was found between PD-ECGF gene expression and the IMD (r(2) = 0.093, P = 0.059). However, tumours with positive expression for both PD-ECGF and VEGF had a higher IMD (P = 0.027). The results of the immunohistochemistry agreed well with the results of the quantitative RT-PCR. The median survival time of the hypervascular group was significantly shorter than that of the hypovascular group (P < 0.0001). In comparing the survival according to PD-ECGF and VEGF gene expression, the median survival time of the patients with positive PD-ECGF expression was significantly shorter than those with negative PD-ECGF expression (P = 0.040). Furthermore, the median survival time of the patients with positive VEGF expression was significantly shorter than those with negative VEGF expression (P = 0.048). However, the Cox multivariate analysis indicated that the IMD and VEGF expression were independent prognostic factors of the various clinicopathologic variables in pancreatic cancer patients (P = 0.0021 and P = 0.0443, respectively). © 1999 Cancer Research Campaign Nature Publishing Group 1999-03 /pmc/articles/PMC2362700/ /pubmed/10188906 http://dx.doi.org/10.1038/sj.bjc.6690248 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Ikeda, N Adachi, M Taki, T Huang, C Hashida, H Takabayashi, A Sho, M Nakajima, Y Kanehiro, H Hisanaga, M Nakano, H Miyake, M Prognostic significance of angiogenesis in human pancreatic cancer |
title | Prognostic significance of angiogenesis in human pancreatic cancer |
title_full | Prognostic significance of angiogenesis in human pancreatic cancer |
title_fullStr | Prognostic significance of angiogenesis in human pancreatic cancer |
title_full_unstemmed | Prognostic significance of angiogenesis in human pancreatic cancer |
title_short | Prognostic significance of angiogenesis in human pancreatic cancer |
title_sort | prognostic significance of angiogenesis in human pancreatic cancer |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362700/ https://www.ncbi.nlm.nih.gov/pubmed/10188906 http://dx.doi.org/10.1038/sj.bjc.6690248 |
work_keys_str_mv | AT ikedan prognosticsignificanceofangiogenesisinhumanpancreaticcancer AT adachim prognosticsignificanceofangiogenesisinhumanpancreaticcancer AT takit prognosticsignificanceofangiogenesisinhumanpancreaticcancer AT huangc prognosticsignificanceofangiogenesisinhumanpancreaticcancer AT hashidah prognosticsignificanceofangiogenesisinhumanpancreaticcancer AT takabayashia prognosticsignificanceofangiogenesisinhumanpancreaticcancer AT shom prognosticsignificanceofangiogenesisinhumanpancreaticcancer AT nakajimay prognosticsignificanceofangiogenesisinhumanpancreaticcancer AT kanehiroh prognosticsignificanceofangiogenesisinhumanpancreaticcancer AT hisanagam prognosticsignificanceofangiogenesisinhumanpancreaticcancer AT nakanoh prognosticsignificanceofangiogenesisinhumanpancreaticcancer AT miyakem prognosticsignificanceofangiogenesisinhumanpancreaticcancer |